SAN RAMON, Calif., Aug. 6, 2019 /PRNewswire/ -- BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced two signi

LINKÖPING, Sweden, Aug. 6, 2019 /PRNewswire/ -- The shareholders of the medical imaging IT and cyber security company Sectra AB (publ) are hereby invited to the Annual General Meeting ("AGM") held on Thursday, September 5, 2019 at 3.30 p.m. (CET) at Collegium, Teknikringen 7, Linköping,

VANCOUVER, British Columbia, Aug. 6, 2019 /PRNewswire/ -- MYM Nutraceuticals Inc., (CSE: MYM.CN) (CSE: MYM) (OTCBB: MYMMF) ("MYM Nutraceuticals" or the "Company") is pleased to announce the incorporation of MYM International Brands Inc. ("MYM International Brands") to focus on the growing global demand for CBD-rich consumer products. The passing of the F

TARRYTOWN, N.Y. and PARIS, Aug. 6, 2019 /PRNewswire/ -- U.S. FDA submission for children planned for 4Q 2019Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 y

TARRYTOWN, N.Y. and PARIS, Aug. 6, 2019 /PRNewswire/ -- Only biologic approved in the European Union for patients aged 12 and above with moderate-to-severe atopic dermatitisApproval is based on Phase 3 trial results showing Dupixent significantly improved disease extent and severity, skin clearance, and itch intens

TOKYO, Aug. 6, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced dosing of the first patient in the SKYLIGHT 1™ Phase 3 pivotal trial for fezolinetant, an investigational oral, non-hormonal compound being studied for the treatment of moderate-to-severe

SUZHOU, China, Aug. 5, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced the signing of a collaboration agreement with Shenogen Pharma Group Ltd. ("Shenogen") to evaluate the combination therapy of Innovent's Tyvyt® (generic name: sin

LOS ANGELES, Aug. 5, 2019 /PRNewswire/ -- Researchers from the Los Angeles Biomedical Research Institute (LA BioMed) have taken a major step toward the creation of vaccine that could neutralize the culprit behind a growing public health crisis. Candida auris, a "superbug" that has caused hundreds of often fatal hospital-acquired infections in

WASHINGTON, Aug. 5, 2019 /PRNewswire/ -- The American Pharmacists Association (APhA) is deeply saddened by the horrific mass shootings that occurred over the weekend in Texas and Ohio where at least 31 people were killed. As an organization representing a profession that provides health care an

ADDISON, Texas, Aug. 5, 2019 /PRNewswire/ -- Next Level Insurance Agency, a Dallas-based healthcare consulting and brokerage firm, announces the recent acquisition of A&H Benefits. This purchase marks the agency's third acquisition over the last 18 months, making Next Level one of the fastest growing boutique employee benefits ag